A Phase 3 interventional study of Belatacept and Tacrolimus in Renal Allograft Recipients, sponsored by Bristol-Myers Squibb. Recruiting at 38 sites in 10 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to continuation of a calcineurin inhibitor-based regimen and their adherence to immunosuppressive medications.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion followed by tapering and discontinuation of the calcineurin inhibitor (CNI)
Biological: Belatacept · Drug: Tacrolimus · Drug: Cyclosporine A · Drug: Mycophenolate Mofetil · Drug: Enteric Coated Mycophenolate Sodium · Drug: Corticosteroids
Drug: Tacrolimus · Drug: Cyclosporine A · Drug: Mycophenolate Mofetil · Drug: Enteric Coated Mycophenolate Sodium · Drug: Corticosteroids
Specified dose on specified days
Also known as: Nulojix
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on Specified days
Proportion of participants who survive with a functional graft with estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 (updated Schwartz formula) at 24 months post-randomization
Time frame: 24 months
Participant and graft survival: Proportion of participants who survive with a functioning graft
Time frame: 6, 12 and 24 months
Participant and graft survival: Proportion of participants who survive
Time frame: 6, 12, and 24 months
Participant and graft survival: Proportion of participants who experience death-censored graft loss
Time frame: 6, 12, and 24 months
Acute rejection: Incidence of clinically suspected biopsy-proven acute rejection (BPAR)
Time frame: 3, 6, 12, and 24 months
Acute rejection: Severity of clinically suspected, biopsy confirmed rejection as determined by locally and centrally reviewed histopathology
Time frame: 3, 6, 12, and 24 months
Renal function as assessed by: Serum creatinine concentration
Time frame: Up to 24 months
Renal function as assessed by: Estimated GFR (eGFR per updated Schwartz combined equation)
Time frame: Up to 24 months
Renal function as assessed by: eGFR per updated bedside Schwartz approximating equation
Time frame: Up to 24 months
Renal function as assessed by: eGFR per Full Age Spectrum (FAS) equation of Potell et al
Time frame: Up to 24 months
Renal function as assessed by: eGFR per age and sex-dependent equation of Pierce et al
Time frame: Up to 24 Months
Proteinuria, as assessed by urinary protein:creatinine ratio (UPCR), as determined from single-voided urine specimens
Time frame: Up to 24 months
Slope of change in eGFR over time, as assessed by baseline-adjusted mean eGFR determinations at protocol-specified study visits
Time frame: Up to 24 months
Adherence to immunosuppressive medications as assessed by variation in calcineurin inhibitor pre-dose whole blood concentrations by summaries over time of monitored adherence to orally administered immunosuppressive medications
Time frame: up to 24 months
Adherence to immunosuppressive medications, as assessed by: Variations in pre-dose concentrations of calcineurin inhibitor in whole blood
Time frame: Up to 24 months
Adherence to immunosuppressive medications, as assessed by: 7-day recall of missed and late doses of each orally administered immuno-suppressive medication at protocol-specified study visits
Time frame: Up to 24 months
Adherence to immunosuppressive medications, as assessed by: Monitoring of compliance with monthly belatacept infusions
Time frame: Up to 24 months
Adherence to immunosuppressive medications, as assessed by: Periodic review of parents' and patients' perceived barriers to adherence to the prescribed immunosuppressive medications regimen
Time frame: Up to 24 months
Mean blood pressure over time
Time frame: Up to 24 months
Mean blood pressure changes from baseline over time
Time frame: Up to 24 months
Intensity of antihypertensive drug therapy, defined as the total number of medications used to maintain BP control
Time frame: Up to 24 months
Monitoring of safety laboratory parameters over time: Mean fasting lipid profiles
Time frame: Up to 24 months
Monitoring of safety laboratory parameters over time: Fasting blood glucose concentrations
Time frame: Up to 24 months
Monitoring of safety laboratory parameters over time: Hemoglobin A1c concentrations
Time frame: Up to 24 months
Donor Specific antibodies (DSA): Proportion of participants with pre-existing anti-human leukocyte antigen (HLA) DSAs at baseline and with de novo anti-HLA DSA post-randomization
Time frame: 6, 12, and 24 months
Immunogenicity of belatacept as determined by the proportion of participants with detectable serum anti-belatacept antibodies
Time frame: 6, 12, and 24 months
Belatacept pre-dose (C0) serum concentrations
Time frame: Up to 24 months
Mean percent belatacept CD86 receptor occupancy
Time frame: Baseline
Post-randomization changes from baseline percent belatacept CD86 receptor occupancy
Time frame: 6, 12, and 24 months
Safety and tolerability of belatacept following conversion: Incidence of Adverse Events (AEs)
Time frame: up to 24 months
Safety and tolerability of belatacept following conversion: Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 24 months
Safety and tolerability of belatacept following conversion: Incidence of laboratory marked abnormalities
Time frame: Up to 24 months
Proportion of participants within each stage of the Tanner staging scale
The Tanner scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult
Time frame: Up to 24 months
Linear growth (height)
Time frame: Up to 24 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jul 2021 (actual). Primary completion is estimated for Dec 2032, 137 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept